Both overall survival and relapse-free survival were not different in low LATS1/2- and high LATS1/2-expressing patients (p = 0.164 and p = 0.576, respectively) (Table 5, Fig. 3f, g); however, an at least apparent advantage of low LATS1/2-expressing serous carcinoma patients for overall survival was noted: the median overall survival of high LATS1/2 expressers was shorter than that of low LATS1/2 expressers. The gene discussed is LATS1; the disease is serous adenocarcinoma.